A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

被引：17
作者：
Iwanaga, Eisaku [1 ]
Nanri, Tomoko [1 ]
Matsuno, Naofumi [1 ]
Kawakita, Toshiro [1 ]
Mitsuya, Hiroaki [1 ]
Asou, Norio [1 ]
机构：
[1] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 8608556, Japan
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 03期
关键词：
PROGNOSTIC IMPACT; JAK2; THERAPY;
D O I：
10.3324/haematol.13283
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：433 / 435
页数：3
相关论文
共 12 条
  • [1] The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications
    Asou, N
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) : 129 - 150
  • [2] Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
    Cairoli, R
    Beghini, A
    Grillo, G
    Nadali, G
    Elice, F
    Ripamonti, CB
    Colapietro, P
    Nichelatti, M
    Pezzetti, L
    Lunghi, M
    Cuneo, A
    Viola, A
    Ferrara, F
    Lazzarino, M
    Rodeghiero, F
    Pizzolo, G
    Larizza, L
    Morra, E
    [J]. BLOOD, 2006, 107 (09) : 3463 - 3468
  • [3] Döhner K, 2006, HAEMATOLOGICA, V91, P1569
  • [4] JAK2V617F mutation in platelets from essential thrombocythemia patients:: correlation with clinical features and analysis of STAT5 phosphorylation status
    Heller, Paula G.
    Lev, Paola R.
    Salim, Juan P.
    Kornblihtt, Laura I.
    Goette, Nora P.
    Chazarreta, Carlos D.
    Glembotsky, Ana C.
    Vassallu, Patricia S.
    Marta, Rosana F.
    Molinas, Felisa C.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 210 - 216
  • [5] Jak2: normal function and role in hematopoietic disorders
    Ihle, James N.
    Gilliland, D. Gary
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) : 8 - 14
  • [6] Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias
    Illmer, Thomas
    Schaich, Markus
    Ehniger, Gerhard
    Thiede, Christian
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 137 - 138
  • [7] Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO
    Kuchenbauer, F.
    Schnittger, S.
    Look, T.
    Gilliland, G.
    Tenen, D.
    Haferlach, T.
    Hiddemann, W.
    Buske, C.
    Schoch, C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (06) : 616 - 619
  • [8] The JAK2 V617F mutation in de novo acute myelogenous leukemias
    Lee, JW
    Kim, YG
    Soung, YH
    Han, KJ
    Kim, SY
    Rhim, HS
    Min, WS
    Nam, SW
    Park, WS
    Lee, JY
    Yoo, NJ
    Lee, SH
    [J]. ONCOGENE, 2006, 25 (09) : 1434 - 1436
  • [9] A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia - The Japan adult leukemia study group AML97 study
    Miyawaki, S
    Sakamaki, H
    Ohtake, S
    Emi, N
    Yagasaki, F
    Mitani, K
    Matsuda, S
    Kishimoto, Y
    Miyazaki, Y
    Asou, N
    Matsushima, T
    Takahashi, M
    Ogawa, Y
    Honda, S
    Ohno, R
    [J]. CANCER, 2005, 104 (12) : 2726 - 2734
  • [10] Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
    Nanri, T
    Matsuno, N
    Kawakita, T
    Suzushima, H
    Kawano, F
    Mitsuya, H
    Asou, N
    [J]. LEUKEMIA, 2005, 19 (08) : 1361 - 1366
12